Quarterly ResultAug 7, 2026, 07:16 AM
Treace Medical Q2 Revenue $45.4M; Raises FY26 Guidance
AI Summary
Treace Medical Concepts reported Q2 2026 financial results with revenue of $45.4 million, a 4% decrease year-over-year, but an improved net loss of $(15.9) million and adjusted EBITDA of $(3.5) million. The company significantly reduced year-to-date cash usage by 57% and ended the quarter with $45.6 million in cash and equivalents. Treace also raised its full-year 2026 revenue guidance to a range of $204 million to $212 million and narrowed its Adjusted EBITDA loss expectation to $3.0 million to $5.0 million, driven by increasing surgeon adoption of its expanded bunion portfolio and new product launches.
Key Highlights
- Q2 2026 revenue was $45.4 million, a 4% decrease from $47.4 million in Q2 2025.
- Reported a Q2 2026 net loss of $(15.9) million, an improvement from $(17.4) million in Q2 2025.
- Adjusted EBITDA for Q2 2026 was $(3.5) million, compared to $(3.6) million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $45.6 million as of June 30, 2026.
- Reduced year-to-date cash usage by 57% or $3.6 million compared to the same period in 2025.
- Raised full-year 2026 revenue guidance to $204 million to $212 million.
- Updated full-year 2026 Adjusted EBITDA loss guidance to $3.0 million to $5.0 million.
- Increased adoption of expanded bunion portfolio to 40% of Lapiplasty® surgeon users.
Price Impact
More from TMCI